CameroonTuberculosis profile
Population  2014 23 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 7.1 (5.1–9.4) 31 (22–41)
Mortality (HIV+TB only) 7.6 (6.3–9.2) 34 (28–40)
Prevalence  (includes HIV+TB) 61 (33–96) 266 (147–421)
Incidence  (includes HIV+TB) 50 (44–56) 220 (195–247)
Incidence (HIV+TB only) 20 (17–23) 88 (75–103)
         
Case detection, all forms (%) 52 (46–59)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.2 (0.3–4.1) 11 (6.2–16)
MDR-TB cases among notified pulmonary
TB cases
460 (63–860) 170 (98–250)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 15 410   1 096
Pulmonary, clinically diagnosed 5 472    
Extrapulmonary 4 060    
       
Total new and relapse 26 038    
Previously treated, excluding relapses 479    
Total cases notified 26 517    
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 5 (<1%) 866 (55%) 871
Laboratory-confirmed RR-/MDR-TB cases     126
Patients started on MDR-TB treatment ***     91
TB/HIV 2014 Number (%)
TB patients with known HIV status 23 006 (87)
HIV-positive TB patients 8 565 (37)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 7 679 (90)
HIV-positive TB patients on antiretroviral therapy (ART) 5 955 (70)
HIV-positive people screened for TB 57 682  
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New cases registered in 2013 (82) 15 102
Previously treated cases registered in 2013 (71) 1 634
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (92) 76
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 1.1
Culture (per 5 million population) 0.7
Drug susceptibility testing (per 5 million population) 0.4
Sites performing Xpert MTB/RIF 3
Is second-line drug susceptibility testing available? Yes, in and outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 2.6
% Funded domestically 7%
% Funded internationally 93%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-02-13 Data: www.who.int/tb/data